Monroe Carell Jr. Children's Hospital at Vanderbilt
Monroe Carell Jr. Children's Hospital at Vanderbilt
Monroe Carell Jr. Children's Hospital at Vanderbilt
Children's Hospital Logo
Connect With Us:

Monroe Carell Jr.
Children's Hospital
at Vanderbilt
2200 Children's Way
Nashville, TN 37232


(615) 936-1000

Children's Hospital Logo
Printer friendly version of this page  E-mail someone a link to this pageBookmark and Share

Pediatric Pulmonary Hypertension Research

 

While there is no cure for many forms of pulmonary hypertension (PH), new insights into the disease are helping children live better lives. Advances in the field through simple observation or more detailed research have led to a better understanding of PH and development of new therapies for its treatment.

By joining with you on your journey and learning from your observations, we at Children's Hospital can better serve you and other patients who may share your experience.

Vanderbilt has a long tradition of research into the causes, consequences, and treatment of various forms of both pediatric and adult PH. We continue that close collaboration today through leading-edge, investigator-initiated research (independent of industry sponsorship), and industry-sponsored research investigations. Our studies range from basic science investigations to clinical trials.

Visit the individual websites of two of our team members for more details:

While never an obligation, participation in research investigations at Vanderbilt is always an option as a part of your child's and family’s experience with PH.

Current pulmonary hypertension research

The Vanderbilt Pediatric Pulmonary Hypertension (PH) Program provides comprehensive diagnostic and therapeutic services to children and families with all forms of pulmonary hypertension. Care is provided by a multidisciplinary team of closely coordinated experts, with traditional coordinated care approaches as well as an array of clinical research opportunities in which patient may participate. Current clinical study opportunities include:

Human research studies

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Sponsor: National Institutes of Health, NHLBI
National PIs: Steven H. Abman, MD and Kenneth Mandl, MD
Site PI at Vanderbilt: Eric D. Austin, MD MSCI

PPHNet is a 10-center North American network of clinical specialists, researchers, and centers bringing a collaborative and multidisciplinary approach to improving care for children with pulmonary vascular disease. This study is a registry of subjects who agree to enroll in a longitudinal evaluation of pediatric patients with pulmonary hypertension over time.

Pediatric Pulmonary Hypertension Network (PPHNet) Biorepository Program
Sponsor: Cardiovascular Medical Research Network
National PIs: Eric D. Austin, MD and Allen Everett, MD

This study is a biorepository program and genomic study of pediatric pulmonary hypertension.

Pulmonary hypertension in children and adults
Sponsor: National Institutes of Health, NHLBI, and the Vanderbilt Institute for Clinical and Translational Research

The Pediatric and Adult Pulmonary Hypertension Programs at Vanderbilt collaborate on a longitudinal study of pulmonary hypertension subjects, and subjects at risk of developing pulmonary hypertension. Studies include clinical, genetic, genomic, and other studies in coordination with our collaborative Vanderbilt Pulmonary Hypertension Research Program.

Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (TOPP-2)
Sponsor: Association for Pediatric Pulmonary Hypertension
International PIs: Fabrizio Canonaco, MD, Simone Lerch, MD, and D. Dunbar Ivy, MD
Site PI: Eric D. Austin, MD MSCI

The TOPP-2 registry is an international, non-interventional, prospective registry including children and adolescents newly diagnosed with pulmonary hypertension (PH) to gain further insights in the disease course and long-term outcome of PH in childhood.

Patients will undergo clinical assessments and receive standard medical care, as determined by treating physicians in their daily clinical practice. The TOPP-2 registry is specifically designed to capture the variables proposed as treatment goals in PePH and the reasons for changes in treatment strategy.

Pulmonary Vein Stenosis Network (PVS Network) Registry Study
Sponsor: Toronto Sick Kids Hospital
International PIs: Christopher Calderone, MD and Rachel Vanderlaan, MD
Site PI: Eric D. Austin, MD MSCI

Our goal is to understand current treatment practices and outcomes, and how best to monitor progression in children with PVS. We will look at retrospective echocardiographic, MRI and CT serial imaging done in this population. We will also look at risk factors that affect outcomes in children with pulmonary vein stenosis/pulmonary vein abnormalities. This will inform clinical decision-making with respect to intervention timing.

Human clinical trials

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years.
Sponsor: United Therapeutics

Oral Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension (PAH)
Sponsor: Eli Lilly and Company


Last Edited: January 27, 2017
Valued Participant of Vanderbilt Health Affiliated Network